Abstract:BackgroundBoth ketamine and methamphetamine have been used for studying the positive, negative, and cognitive symptoms, and dopaminergic and GABAergic dysfunction observed in acute schizophrenia. We aimed to explore and compare the prevalence and factor structure of psychotic symptoms in chronic ketamine and methamphetamine users.MethodsWe recruited chronic ketamine and methamphetamine users from the Guangzhou Baiyun and Kangda voluntary drug rehabilitation centres in the Hunan Province, China. All these participants met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for lifetime ketamine or methamphetamine dependence determined from the Structured Clinical Interview. Participants were excluded if they met criteria for other substance dependence (excluding nicotine) at any time. All participants gave a full history of psychiatric symptoms. We used The Positive and Negative Syndrome Scale (PANSS) to assess the psychotic symptoms in these two groups. Independent sample t-tests or χ2-square test were done to determine group differences. The protocol was approved by the university ethics committee (S163, 2011).FindingsWe recruited 344 chronic ketamine users (34 were female; mean age 26·8 years, SD 5·43; mean years of education 11·6 years, SD 2·45) and 456 chronic methamphetamine users (28 were female; mean age 29·3 years SD 6·33, mean years of education 11·1 years, SD 2·78) between Jan 1, 2012, to Dec 31, 2015. 183 (53%) of 344 ketamine users and 375 (82%) of 456 methamphetamine users (χ2 t=78·37, p<0·0001) had psychiatric symptoms, with a mean duration of 23·5 months (SD 24·58) for ketamine users and 15·0 months (SD 19·42) for methamphetamine users (t=4·05, p<0·0001). The mean age when first having psychotic symptoms was 25·4 years (SD 5·55) in ketamine users and 28·5 years (6·33) in methamphetamine users (t=–5·84, p<0·0001). Mean scores on PANSS TOTAL were 52·6 (SD 23·34) in ketamine users and 61·7 (29·61) in methamphetamine users (t=–4·84, p<0·0001). Mean scores for ketamine and methamphetamine use groups on positive, negative, and general subscales were 10·8 (SD 5·45) versus 15·0 (8·26; t=–8·80, p<0·0001), 12·2 (6·91) versus 14·5 (8·68; t=–4·07, p<0·0001), and 29·7 (12·98) versus 32·2 (15·22; t=–2·55, p=0·011), respectively.InterpretationThis study provides first evidence for comparing psychotic symptoms in chronic ketamine and chronic methamphetamine users. The findings suggest that chronic methamphetamine users have higher risk of suffering from psychiatric symptoms and more severity of chronic drug-induced schizophrenia-like symptoms than do chronic ketamine users. These findings might provide some implications for pharmacological (glutamatergic and dopaminergic) models of schizophrenia.FundingNatural Science Foundation of China (81100996 to YL, and 81371480 to JT). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Trait anger as a predictor of dangerous driving behaviour amongst people who use methamphetamine

Predictors of Aggressive Behavior While under the Influence of Illicit Drugs among Young Adult Methamphetamine Users

N-Acetyl and Glutamatergic Neurometabolites in Perisylvian Brain Regions of Methamphetamine Users

Acute methamphetamine and alcohol usage alters gaze behaviour during driving: A randomised, double-blind, placebo-controlled study

Correlates of Aggression in Men With Methamphetamine Use Disorder: Childhood Trauma and Methamphetamine-Use Characteristics

Problematic substance use and implications for road safety: An investigation on psychological dysfunction and risky driving styles

Anxiety and depression among a community‐recruited cohort of people who use methamphetamine: A longitudinal analysis

Posttraumatic Stress Disorder Symptoms, Emotion Dysregulation, and Aggressive Behavior Among Incarcerated Methamphetamine Users

Multigroup invariance of measure for angry drivers (MAD) scale using a representative sample of drivers in Australia

Impulsiveness, suicide, and aggression in a sample of patients with disorders of methyl amphetamine use

Psychiatric Symptoms in Individuals Who Use Ketamine Versus Methamphetamine—implications for Glutamatergic and Dopaminergic Model for Schizophrenia: a Cohort Study

What contributes to drug driving? An exploratory investigation into the influence of problematic substance use, roadside testing and alternative transport options

Is cannabis associated with more than just driving impairment? An investigation into the psychological dysfunctioning and driving behaviours of active cannabis users

Mindfulness and clinical correlates in methamphetamine use disorder

Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada

Development and validation of the beliefs about driver anger questionnaire: A scale to predict anger propensity on the road

Associations between alexithymia, parental rearing styles, and frequency of drug use in male methamphetamine dependence patients

A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms

Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers.

Increased AGE–RAGE axis stress in methamphetamine abuse and methamphetamine‐induced psychosis: Associations with oxidative stress and increased atherogenicity

Relapse of drunk driving and association with traffic accidents, alcohol-related problems and biomarkers of impulsivity